Rivaroxaban n/N (%) | Standard therapy n/N (%) | ||
---|---|---|---|
Age, years | <65 | 7/134 (5.2) | 5/133 (3.8) |
65–75 | 3/52 (5.8) | 9/57 (15.8) | |
>75 | 3/33 (9.1) | 6/28 (21.4) | |
Creatinine clearance, mL/min | ≥80 | 8/117 (6.8) | 4/116 (3.4) |
50–<80 | 3/75 (4.0) | 10/72 (13.9) | |
<50 | 1/19 (5.3) | 6/28 (21.4) | |
Body weight, kg | ≤50 | 0/3 | 2/11 (18.2) |
>50–70 | 9/134 (6.7) | 14/134 (10.4) | |
>70–90 | 3/79 (3.8) | 4/69 (5.8) | |
>90 | 0/1 | 0/4 | |
Fragility* | No | 9/174 (5.2) | 13/172 (7.6) |
Yes | 4/45 (8.9) | 7/46 (15.2) |